How to monitor response to biologics in children with severe asthma

Area of Science:

• Pediatric Pulmonology
• Immunology
• Pharmacology

Background:

• Severe paediatric asthma presents significant health and financial challenges.
• Biologics, targeting specific inflammatory pathways, are transforming management for children and adolescents.
• Current approved biologics include anti-immunoglobulin E, anti-interleukin-5, anti-interleukin-5 receptor, anti-interleukin-4/13, and anti-thymic stromal lymphopoietin therapies.

Purpose of the Study:

• To review strategies for monitoring treatment response to biologics in severe paediatric asthma.
• To discuss the role of asthma biomarkers in optimizing biologic therapy.
• To explore emerging therapies and identify research gaps for biologics in pediatric asthma.

Main Methods:

• This is a narrative review, building on a previous article that summarized clinical trial findings.
• Focuses on real-world data, monitoring strategies, and biomarker utility.
• Identifies current research gaps and future directions for biologic use.

Main Results:

• Limited real-world data exists on the long-term efficacy and safety of biologics in children and adolescents.
• Guidelines for initiating and monitoring biologics vary globally, lacking consensus.
• Emerging therapies and biomarker research hold promise for optimizing treatment.

Conclusions:

• Further real-world evidence is crucial for understanding long-term biologic outcomes in severe paediatric asthma.
• Standardized monitoring strategies and biomarker integration are needed for effective treatment.
• Continued research into emerging therapies and addressing knowledge gaps will optimize biologics use in this population.